You are viewing the site in preview mode
Skip to main content
|
Variables (mean ± SD,)
|
Total
|
|---|
|
Gender
|
|
Male
|
27
|
|
Female
|
20
|
|
Age, years
|
50.8 ± 12.0
|
|
Indications for primary PPV
|
|
VH
|
44
|
|
VH and TRD
|
3
|
|
Days of VH post PPV,
|
34.9 ± 42.7
|
|
Category of VH post PPV
|
|
Early VH
|
33
|
|
Delayed VH
|
13
|
|
Severe persistent VH
|
1
|
|
Diagnosis
|
|
T1DM
|
4
|
|
T2DM
|
43
|
|
Lens status
|
|
Pseudophakic
|
21
|
|
Phakic
|
26
|
|
Times of Air-fluid exchange procedure
|
|
= 1
|
42
|
|
= 2
|
4
|
|
= 3
|
1
|
|
Additional ocular treatment
|
|
No treatment
|
5
|
|
Only photocoagulation
|
41
|
|
Laser plus Conbercept
|
1
|
|
Follow-up post last exchange, months
|
22.7 ± 13.6
|
- VH Vitreous hemorrhage; TRD Tractional retinal detachment; PPV Pars plana vitrectomy; DM Diabetes mellitus. Conbercept: an anti-VEGF drug for intraocular use in China
